LAUSANNE, Switzerland--(BUSINESS WIRE)--Regulatory News:

瑞士洛桑——（商业新闻短讯）——监管新闻：

Timeline®, a pioneering Swiss consumer biotech company at the forefront of longevity research, is proud to announce the successful completion of its landmark immune aging clinical study, MitoImmune, using Mitopure (proprietary Urolithin A). Additionally, the company has partnered on two new clinical trials in collaboration with prestigious research institutions to expand its applications of Mitopure for healthy aging.

Timeline®是一家领先于长寿研究前沿的瑞士消费者生物技术公司，它自豪地宣布，使用Mitopure（专有尿石素a）成功完成了其里程碑式的免疫衰老临床研究MitoImmune。此外，该公司还与著名研究机构合作进行了两项新的临床试验，以扩大Mitopure在健康衰老中的应用。

Timeline, backed by Nestlé and L'Oréal Group investments, builds on 15 years of research and multiple clinical studies..

时间表由雀巢和欧莱雅集团投资支持，建立在15年的研究和多项临床研究的基础上。。

'Our mission has always been to pioneer research that unlocks clinically proven interventions to help people stay healthier for longer. These results open a totally new approach to directly impact our immune cells and help restore their functionality during aging.' - Chris Rinsch, PhD, Co-Founder and President of Timeline..

“我们的使命一直是开创研究，解开临床证明的干预措施，以帮助人们保持更长时间的健康。这些结果开辟了一种全新的方法，可以直接影响我们的免疫细胞，并有助于在衰老过程中恢复其功能Chris Rinsch博士，Timeline联合创始人兼总裁。。

'This is groundbreaking research that helps us better understand how we can counter the age-related decline of our immune system and shows us that we can rewire our bodies defense with targeted mitochondrial interventions like Mitopure.' - Dr. Eric Verdin, CEO and President of the Buck Institute for Research on Aging..

“这是一项开创性的研究，有助于我们更好地了解如何应对与年龄相关的免疫系统下降，并向我们表明，我们可以通过有针对性的线粒体干预措施（如Mitopure）重新连接我们的身体防御。”埃里克·威尔丁博士，巴克老龄化研究所首席执行官兼总裁。。

'Our collaboration with Timeline on the MitoImmune study has provided invaluable insights into the intersection of mitochondrial health and immune function. These findings may prove important for the oncology community.' - Dr. Dominic Denk, MD, Principal Investigator of MitoImmune Study.

“我们与Timeline在线粒体免疫研究中的合作为线粒体健康和免疫功能的交叉提供了宝贵的见解。这些发现可能对肿瘤学界很重要Dominic Denk博士，医学博士，MitoImmune研究的首席研究员。

The MitoImmune study is an unprecedented intervention-based assessment of immune aging. This randomized, placebo-controlled study was conducted in collaboration with the Georg-Speyer-Haus Institute for Tumor and Experimental Therapy and the Buck Institute of Aging in California, USA. The study enrolled 50 middle-aged adults over a four-week intervention with Mitopure.

MitoImmune研究是一项前所未有的基于干预的免疫衰老评估。这项随机安慰剂对照研究是与美国加利福尼亚州乔治·斯派尔·豪斯肿瘤与实验治疗研究所和巴克衰老研究所合作进行的。该研究招募了50名中年成年人，为期四周的Mitopure干预。

T-cells, key for fighting infections and age-related diseases, decline dramatically in both number and quality with age. The key study co-primary endpoints were an increase of the youthful naive CD8 T-cells, and an improvement in mitochondrial activity of these T-cells. Both the study primary endpoints were successfully met with Mitopure intervention compared to placebo.

T细胞是抵抗感染和与年龄有关的疾病的关键，随着年龄的增长，T细胞的数量和质量都急剧下降。关键研究的共同主要终点是年轻幼稚CD8 T细胞的增加，以及这些T细胞线粒体活性的改善。与安慰剂相比，两项研究的主要终点均成功达到Mitopure干预。

Other key secondary endpoints including reduction of inflammaging were also met. The topline results from the study were presented on May 5, 2024 at the leading immunology conference, American Association of Immunologists (AAI), in Chicago..

还满足了其他关键的次要终点，包括减少炎症。该研究的主要结果于2024年5月5日在芝加哥举行的美国免疫学家协会（AAI）主要免疫学会议上发表。。

Building on the success of the research on Mitopure to date, the company is pleased to support two additional investigator-led clinical trials with esteemed partners:

基于迄今为止Mitopure研究的成功，该公司很高兴与尊敬的合作伙伴支持另外两项由研究者主导的临床试验：

In collaboration with the National Institute of Aging, we're investigating the impact of Mitopure on glucose metabolism in middle-aged overweight adults. This study aims to uncover the potential of Mitopure to improve metabolic health and mitigate age-related metabolic decline.

与美国国家老龄化研究所合作，我们正在调查Mitopure对中年超重成年人葡萄糖代谢的影响。这项研究旨在揭示Mitopure改善代谢健康和缓解与年龄相关的代谢下降的潜力。

Timeline is also collaborating with the National Institute of Cancer that is evaluating the impact of Mitopure on oxidative stress in adults diagnosed with prostate cancer. This new study seeks to uncover the potential of Mitopure in managing oxidative stress and its implications for cancer patients.

Timeline还与美国国家癌症研究所（National Institute of Cancer）合作，该研究所正在评估Mitopure对被诊断患有前列腺癌的成年人的氧化应激的影响。这项新研究旨在揭示Mitopure在管理氧化应激方面的潜力及其对癌症患者的影响。

For more information about Timeline and our ongoing research initiatives, please visit www.timeline.com/studies.

有关时间表和我们正在进行的研究计划的更多信息，请访问www.Timeline.com/studies。

About Timeline

关于时间线

Timeline (parent company Amazentis) is a pioneering Swiss health science company committed to revolutionizing the longevity industry with its groundbreaking, clinically proven, proprietary ingredient Mitopure®. Offering a comprehensive approach to cellular health, Timeline incorporates the benefits of Mitopure inside its next generation nutritional supplements and topical skin health products.

Timeline（母公司Amazentis）是一家开创性的瑞士健康科学公司，致力于以其开创性的、经临床验证的专有成分Mitopure®彻底改变长寿行业。Timeline提供了一种全面的细胞健康方法，它将Mitopure的益处纳入了下一代营养补充剂和局部皮肤保健产品中。

With more than a decade of expertise in aging science research, Timeline seeks to push the boundaries of human healthspan, contributing to a future where everyone can live longer, healthier lives. The company is backed by over 15 years of research by distinguished scientists, multiple clinical studies, and over 50 global patents.

Timeline拥有十多年的衰老科学研究专业知识，旨在突破人类健康的界限，为每个人都能活得更长、更健康的未来做出贡献。该公司拥有杰出科学家超过15年的研究、多项临床研究和50多项全球专利。

Nestlé Health Science and L’Oréal are investors in the company. www.timeline.com.

雀巢健康科学和欧莱雅是该公司的投资者。www.timeline.com。